The Start-Up Market at CPHI Barcelona brings together 27 start-ups, innovators, and small enterprises from across the pharma landscape.
As CPHI Barcelona approaches, the pharmaceutical world is gearing up to explore promising innovations that could shape the future of healthcare. This year is historic for CPHI, as it introduces a dedicated exhibition zone exclusively for start-ups, which are the innovation hubs of the industry. As part of its overarching mission to accelerate the journey of innovative medicines to patients worldwide, CPHI is shining a spotlight on some of the most promising early-stage technological innovations poised to impact the global pharmaceutical landscape. In this context, we had the privilege to engage with two emerging start-ups, one in the realm of devices and the other specializing in enhancing solubility, both offering unique solutions set to reshape the pharmaceutical landscape.
Read this article in the Trends in Formulation ebook.
This article was written by the CPHI Content Team.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.